|
1
|
McKillop IH, Moran DM, Jin X and Koniaris
LG: Molecular pathogenesis of hepatocellular carcinoma. J Surg Res.
136:125–135. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Llovet JM, Burroughs A and Bruix J:
Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar
|
|
3
|
Trevisani F, Cantarini MC, Wands JR and
Bernardi M: Recent advances in the natural history of
hepatocellular carcinoma. Carcinogenesis. 29:1299–1305. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kusakabe A, Tanaka Y, Orito E, Sugauchi F,
Kurbanov F, Sakamoto T, Shinkai N, Hirashima N, Hasegawa I, Ohno T,
et al: A weak associatioon between occult HBV infection and non-B
non-C hepatocellular carcinoma in Japan. J Gastroenterol.
42:298–305. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
El-Serag HB, Siegel AB, Davila JA, Shaib
YH, Cayton-Woody M, McBride R and McGlynn KA: Treatment and
outcomes of treating of hepatocellular carcinoma among Medicare
recipients in the United States: a population-based study. J
Hepatol. 44:158–166. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wakamatsu T, Nakahashi Y, Hachimine D,
Seki T and Okazaki K: The combination of glycyrrhizin and
lamivudine can reverse the cisplatin resistance in hepatocellular
carcinoma cells through inhibition of multidrug
resistance-associated proteins. Int J Oncol. 31:1465–1472.
2007.
|
|
7
|
Pérez-Tomás R: Multidrug resistance:
retrospect and prospects in anti-cancer drug treatment. Curr Med
Chem. 13:1859–1876. 2006.PubMed/NCBI
|
|
8
|
Clarke R, Currier S, Kaplan O, Lovelace E,
Boulay V, Gottesman MM and Dickson RB: Effect of P-glycoprotein
expression on sensitivity to hormones in MCF-7 human breast cancer
cells. J Natl Cancer Inst. 84:1506–1512. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Choi C: ABC transporters as multidrug
resistance mechanisms and the development of chemosensitizers for
their reversal. Cancer Cell Int. 5:302005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cole SP, Bhardwaj G, Gerlach JH, Mackie
JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM and
Deeley RG: Overexpression of a transporter gene in a
multidrug-resistant human lung cancer cell line. Science.
258:1650–1654. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cox DS, Scott KR, Gao H, Raje S and
Eddington ND: Influence of multidrug resistance (MDR) proteins at
the blood-brain barrier on the transport and brain distribution of
enaminone anticonvulsants. J Pharm Sci. 90:1540–1552. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Coley HM: Mechanisms and strategies to
overcome chemotherapy resistance in metastatic breast cancer.
Cancer Treat Rev. 34:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xiang W, Gao A, Liang H, Li C, Gao J, Wang
Q, Shuang B, Zhang J, Yan Y and Wang X: Reversal of
P-glycoprotein-mediated multidrug resistance in vitro by milbemycin
compounds in adriamycin-resistant human breast carcinoma
(MCF-7/adr) cells. Toxicol in Vitro. 24:1474–1481. 2010. View Article : Google Scholar
|
|
14
|
Xu HB, Xu LZ, Li L, Fu J and Mao XP:
Reversion of P-glycoprotein-mediated multidrug resistance by
guggulsterone in multidrug-resistant human cancer cell lines. Eur J
Pharmacol. 694:39–44. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hoffmeyer S, Burk O, von Richter O, Arnold
HP, Brockmöller J, Johne A, Cascorbi I, Gerloff T, Roots I,
Eichelbaum M and Brinkmann U: Functional polymorphisms of the human
multidrug-resistance gene: multiple sequence variations and
correlation of one allele with P-glycoprotein expression and
activity in vivo. Proc Natl Acad Sci USA. 97:3473–3478. 2000.
View Article : Google Scholar
|
|
16
|
Gottesman MM and Ling V: The molecular
basis of multidrug resistance in cancer: the early years of
P-glycoprotein research. FEBS Lett. 580:998–1009. 2006.PubMed/NCBI
|
|
17
|
Li J, Xu LZ, He KL, Guo WJ, Zheng YH, Xia
P and Chen Y: Reversal effects of nomegestrol acetate on multidrug
resistance in adriamycin-resistant MCF7 breast cancer cell line.
Breast Cancer Res. 3:253–263. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Middleton E Jr, Kandaswami C and
Theoharides TC: The effects of plant flavonoids on mammalian cells:
implications for inflammation, heart disease, and cancer. Pharmacol
Rev. 52:673–751. 2000.PubMed/NCBI
|
|
19
|
Li YL, Gan GP, Zhang HZ, Wu HZ, Li CL,
Huang YP, Liu YW and Liu JW: A flavonoid glycoside isolated from
Smilax china L. rhizome in vitro anticancer effects on human
cancer cell lines. J Ethnopharmacol. 113:115–124. 2007.
|
|
20
|
Diaz JG, Carmona AJ, Torres F, Quintana J,
Estévez F and Herz W: Cytotoxic activities of flavonoid glycoside
acetates from Consolida oliveriana. Planta Med. 74:171–174.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wesołowska O: Interaction of
phenothiazines, stilbenes and flavonoids with multidrug
resistance-associated transporters, P-glycoprotein and MRP1. Acta
Biochim Pol. 58:433–448. 2011.PubMed/NCBI
|
|
22
|
Wang Z, Wang H, Wu J, Zhu D, Zhang X, Ou
L, Yu Y and Lou Y: Enhanced co-expression of beta-tubulin III and
choline acetyltransferase in neurons from mouse embryonic stem
cells promoted by icaritin in an estrogen receptor-independent
manner. Chem Biol Interact. 179:375–385. 2009. View Article : Google Scholar
|
|
23
|
Wo YB, Zhu DY, Hu Y, Wang ZQ, Liu J and
Lou YJ: Reactive oxygen species involved in prenylflavonoids,
icariin and icaritin, initiating cardiac differentiation of mouse
embryonic stem cells. J Cell Biochem. 103:1536–1550. 2008.
View Article : Google Scholar
|
|
24
|
Zhang G, Qin L, Sheng H, Wang XL, Wang YX,
Yeung DK, Griffith JF, Yao XS, Xie XH, Li ZR, Lee KM and Leung KS:
A novel semisynthesized small molecule icaritin reduces incidence
of steroid-associated osteonecrosis with inhibition of both
thrombosis and lipid-deposition in a dose-dependent manner. Bone.
44:345–356. 2009. View Article : Google Scholar
|
|
25
|
Wang ZQ and Lou YJ:
Proliferation-stimulating effects of icaritin and desmethylicaritin
in MCF-7 cells. Eur J Pharmacol. 504:147–153. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Huang X, Zhu D and Lou Y: A novel
anticancer agent, icaritin, induced cell growth inhibition, Gl
arrest and mitochondrial transmenbrane potential drop in human
prostate carcinoma PC-3 cells. Eur J Pharmacol. 564:26–36. 2007.
View Article : Google Scholar
|
|
27
|
Hall MD, Brimacombe KR, Varonka MS,
Pluchino KM, Monda JK, Li J, Walsh MJ, Boxer MB, Warren TH, Fales
HM and Gottesman MM: Synthesis and structure-activity evaluation of
isatin-β-thiosemicarbazones with improved selective activity toward
multidrug-resistant cells expressing P-glycoprotein. J Med Chem.
54:5878–5889. 2011.
|
|
28
|
Huang C, Xu D, Xia Q, Wang P, Rong C and
Su Y: Reversal of P-glycoprotein-mediated multidrug resistance of
human hepatic cancer cells by Astragaloside II. J Pharm Pharmacol.
64:1741–1750. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yan F, Wang XM, Liu ZC, Pan C, Yuan SB and
Ma QM: JNK1, JNK2, and JNK3 are involved in P-glycoprotein-mediated
multidrug resistance of hepatocellular carcinoma cells.
Hepatobiliary Pancreat Dis Int. 9:287–295. 2010.PubMed/NCBI
|
|
30
|
Eicher C, Dewerth A, Kirchner B, Warmann
SW, Fuchs J and Armeanu-Ebinger S: Development of a drug resistance
model for hepatoblastoma. Int J Oncol. 38:447–454. 2010.PubMed/NCBI
|
|
31
|
Minotti G, Menna P, Salvatorelli E, Cairo
G and Gianni L: Anthracyclines: molecular advances and
pharmacologic developments in antitumor activity and
cardiotoxicity. Pharmacol Rev. 56:185–229. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Barrand MA, Heppell-Parton AC, Wright KA,
Rabbitts PH and Twentyman PR: A 190-kilodalton protein
overexpressed in non-P-glycoprotein-containing multidrug-resistant
cells and its relationship to the MRP gene. J Natl Cancer Inst.
86:110–117. 1994. View Article : Google Scholar
|
|
33
|
Mehta K: High levels of transglutaminase
expression in doxorubicin-resistant human breast carcinoma cells.
Int J Cancer. 58:400–406. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tong JS, Zhang QH, Huang X, Fu XQ, Qi ST,
Wang YP, Hou Y, Sheng J and Sun QY: Icaritin causes sustained
ERK1/2 activation and induces apoptosis in human endometrial cancer
cells. PLoS One. 6:e167812011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Borst P and Schinkel AH: What have we
learnt thus far from mice with disrupted P-glycoprotein genes? Eur
J Cancer. 32:985–990. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kumar YS, Adukondalu D, Sathish D, Vishnu
YV, Ramesh G, Latha AB, Reddy PC, Sarangapani M and Rao YM:
P-Glycoprotein- and cytochrome P-450-mediated herbal drug
interactions. Drug Metabol Drug Interact. 25:3–16. 2010. View Article : Google Scholar : PubMed/NCBI
|
